natgillin/translations-raw huggingface dataset:
Diarre
Arthralgia
Nyrer og urinveje Knogler, led, muskler og bindevæv
Metabolism and nutrition disorders
Arthralgier
Increased Appetite
Metabolisme og ernæring Almene symptomer og reaktioner på administrationsstedet
General disorders and administration site conditions
Øget appetit Træthed
Fatigue
Der er dog observeret neurologiske forstyrrelser (såsom cerebellare symptomer, diplopi, lateral nystagmus, nedsat psykomotorisk tempo, håndbevægelser og aksial hypotoni) hos børn, som igennem flere år frivilligt har fået ordineret mere end 2, 5 gange den maksimalt anbefalede dosis på 100 mg/ kg dagligt.
However, neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100 mg/ kg/ day for several years.
Jernkelerende stoffer, ATC- kode:
Iron chelating agents, ATC code:
Det aktive stof er deferiprone (3- hydroxy- 1, 2- dimetylpyridin- 4- et), en bidentat ligand, som binder sig til jern i molarforholdet 3: 1.
The active substance is deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one), a bidentate ligand which binds to iron in a 3:1 molar ratio.
Kliniske undersøgelser har vist, at deferiprone er effektivt til fremme af jernudskillelse, og at en dosis på 25 mg/ kg tre gange daglig kan forebygge progression af jernakkumulation vurderet ved serumferritin hos patienter med transfusions- afhængig thalassaemia.
Clinical studies have demonstrated that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/ kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia.
Deferiprone er undersøgt hos 247 patienter i to fase III- undersøgelser og et såkaldt ‘ compassionate use ’ program.
6 Deferiprone has been investigated in 247 patients in two phase III trials and a compassionate use programme.
Serum ferritin blev valgt som primært effektkriterium i undersøgelserne.
Serum ferritin was chosen as the primary efficacy criterion in the studies.
I en undersøgelse af to års varighed blev deferiprone sammenlignet med deferoxamin.
In one study of two-year duration deferiprone was compared to deferoxamine.
Middelkoncentrationerne af serum ferritin var ikke signifikant forskellige i de to behandlingsgrupper,
The mean serum ferritin levels were not significantly different in the two treatment groups, but mean hepatic iron concentration in deferiprone treated patients seems to increase more than in deferoxamine treated patients.
Ved den anbefalede dosering kunne deferiprone derfor være mindre effektiv end deferoxamine.
Therefore deferiprone at the recommended dose could be less effective than deferoxamine.
Den anden var en understøttende, åben, ikke- komparativ undersøgelse.
The other study was a supportive open, non-comparative study.
I denne undersøgelse bibeholdt patienterne serum ferritin- værdier på samme niveau som før undersøgelsen.
In this study patients maintained serum ferritin values at pre-study levels.
Den primære parameter var incidensen af agranulocytose, som optrådte med en frekvens på 1, 2%.
The primary end-point was the incidence of agranulocytosis, which occurred at a frequency of 1.2%.
Absorption Deferiprone absorberes hurtigt fra den øverste del af den gastro- intestinale kanal.
Absorption Deferiprone is rapidly absorbed from the upper part of the gastrointestinal tract.
Forekomst af serumkoncentrationsspidser er rapporteret 45 til 60 minutter efter en enkeltdosis hos fastende patienter.
Peak serum concentration is reported to occur 45 to 60 minutes following a single dose in fasted patients.
Dette kan forlænges til 2 timer hos patienter, der har indtaget føde.
This may be extended to 2 hours in fed patients.
Efter en dosis på 25 mg/ kg er der detekteret lavere spidskoncentrationer i serum hos patienter, der havde indtaget føde (85 μmol/ l) end ved fastende tilstand (126 μmol/ l), selv om der ikke var noget fald i mængden af absorberet deferiprone, da det blev givet sammen med føde.
Following a dose of 25 mg/ kg, lower peak serum concentrations have been detected in patients in the fed state (85 μ mol/ l) than in the fasting state (126 μ mol/ l), although there was no decrease in the amount of deferiprone absorbed when it was given with food.
Biotransformation Deferiprone metaboliseres primært til et glucuronidkonjugat.
Biotransformation Deferiprone is metabolised predominantly to a glucuronide conjugate.
Denne metabolit mangler jernbindingsevne på grund af inaktivering af 3- hydroxy- gruppen i deferiprone.
This metabolite lacks iron-binding capability due to inactivation of the 3-hydroxy group of deferiprone.
Spidskoncentrationer i serum for glucuronid forekommer 2 til 3 timer efter indgivelse af deferiprone.
Peak serum concentrations of the glucuronide occur 2 to 3 hours after administration of deferiprone.
75% til 90% af den indtagne dosis rapporteres som værende genfundet i urinen i løbet af de første 24 timer i form af frit deferiprone, glucuronidmetabolitten og jerndeferipronekompleks.
Elimination In humans, deferiprone is eliminated mainly via the kidneys; 75% to 90% of the ingested dose is reported as being recovered in the urine in the first 24 hours, in the form of free deferiprone, the glucuronide metabolite and the iron-deferiprone complex.
Der er udført prækliniske forsøg på dyrearter såsom mus, rotter, kaniner og hunde samt aber.
Non-clinical studies have been conducted in animal species including mice, rats, rabbits, dogs and monkeys.
De fleste resultater hos ikke ionbelastede dyr i doser på 100 mg/ kg/ dag og derover var hæmatologiske virkninger, så som hypocellularitet i knoglemarven og reducerede WBC, RBC og/ eller trombocyttal i perifert blod.
The most common findings in non-iron-loaded animals at doses of 100 mg/ kg/ day and above were hematologic effects such as bone marrow hypocellularity, and decreased WBC, RBC and/ or platelet counts in peripheral blood.
Ved doser på 100 mg/ kg/ dag eller derover hos ikke- ionbelastede dyr blev der rapporteret om atrofi i thymus, lymfoide væv og testis samt hypertrofi i binyrerne.
Atrophy of the thymus, lymphoid tissues, and testis, and hypertrophy of the adrenals, were reported at doses of 100 mg/ kg/ day or greater in non-iron-loaded animals.
Der er ikke gennemført carcinogenitetsundersøgelser på dyr med deferiprone.
No carcinogenicity studies in animals have been conducted with deferiprone.
Deferiprones genotoksiske potentiale blev evalueret i en række in vitro - og in vivo- forsøg.
The genotoxic potential of deferiprone was evaluated in a set of in vitro and in vivo tests.
Deferiprone udviste ikke nogen direkte mutagene egenskaber; men det udviste klastogene egenskaber ved in vitro- analyser og in vivo hos dyr.
Deferiprone did not show direct mutagenic properties; however, it did display clastogenic characteristics in in vitro assays and in vivo in animals.
Deferiprone var teratogent og embryotoksisk ved reproduktive undersøgelser hos ikke- ionbelastede rotter og kaniner i doser på mindst 25 mg/ kg/ dag.
Deferiprone was teratogenic and embryotoxic in reproductive studies in non-iron-loaded rats and rabbits at doses at least as low as 25 mg/ kg/ day.
Der er ikke gennemført prænatale og postnatale reproduktionsundersøgelser på dyr.
No prenatal and postnatal reproductive studies have been conducted in animals.
Tabletkerne Mikrokrystallinsk cellulose Magnesiumstearat Kolloid siliciumdioxid
Tablet core Microcrystalline cellulose Magnesium stearate Colloidal silicon dioxide
Overtræk Hypromellose Macrogol Titaniumdioxid
Coating Hypromellose Macrogol Titanium dioxide
Må ikke opbevares over 30ºC
Do not store above 30ºC
HDPE- glas med børnesikret lukning.
High density polyethylene (HDPE) bottles with child resistant closure (polypropylene).
Darwinweg 20 2333 CR Leiden Holland
Darwinweg 20 2333 CR Leiden Netherlands
25/ 08/ 1999 Dato for sidste fornyelse:
25/ 08/ 1999 Date of latest renewal:
Ferriprox 100 mg/ ml oral opløsning
Ferriprox 100 mg/ ml oral solution
Hver ml oral opløsning indeholder 100 mg deferiprone.
Each ml of oral solution contains 100 mg deferiprone.
Hver ml oral opløsning indeholder 0, 4 mg Sunset Yellow (E110).
Each ml of oral solution contains 0.4 mg Sunset Yellow (E110).
Klar, rød- orange væske.
Clear, reddish orange coloured liquid.
Dosering pr. kilogram legemsvægt bør beregnes til nærmeste 2, 5 ml.
Dose per kilogram body weight should be calculated to the nearest 2.5 ml.
75 mg/ kg/ daglig anvendes den mængde oral opløsning, der foreslås i følgende skema for patientens legemsvægt.
To obtain a dose of about 75 mg/ kg/ day, use the volume of oral solution suggested in the following table for the body weight of the patient.
10
Sample body weights at 10 kg increments are listed.
Kropsvægt (kg) 20 30 40 50 60 70 80 90
(kg) 20 30 40 50 60 70 80 90
daglig dosis (mg) 1500 2250 3000 3750 4500 5250 6000 6750
(mg) 1500 2250 3000 3750 4500 5250 6000 6750
Dosis gange daglig) 500 750 1000 1250 1500 1750 2000 2250
(mg, three times/ day) 500 750 1000 1250 1500 1750 2000 2250
ml oral opløsning (tre gange daglig) 5, 0 7, 5 10, 0 12, 5 15, 0 17, 5 20, 0 22, 5
times/ day) 5.0 7.5 10.0 12.5 15.0 17.5 20.0 22.5
4. 3 Kontraindikationer
Contraindications
Risikoen for agranulocytose og neutropeni er højere, hvis ANC- tallet i starten er mindre end 1, 5 x 109/ l.
The risk of agranulocytosis and neutropenia is higher, if the baseline absolute neutrophil count (ANC) is less than 1.5x109/ l.
Giv patienten besked på omgående at ophøre med indtagelsen af deferiprone og alle øvrige lægemidler, som muligvis kan forårsage neutropeni.
Instruct the patient to immediately discontinue deferiprone and all other medicinal products with a potential to cause neutropenia.
Det anbefales, at der efter restituering efter neutropeni fortsat indhentes ugentlige CBC, WBC, neutrofil - og trombocyttal i tre på hinanden følgende uger for at sikre, at patienten er helt restitueret.
It is recommended that following recovery from neutropenia, weekly CBC, WBC, neutrophil and platelet counts continue to be obtained for three consecutive weeks, to ensure that the patient recovers fully.
11 I tilfælde af alvorlig neutropeni eller agranulocytose:
10 In the event of severe neutropenia or agranulocytosis:
Hjælpestoffer Ferriprox oral opløsning indeholder farvestoffet Sunset Yellow (E110), som kan forårsage allergiske reaktioner.
Excipients Ferriprox oral solution contains the colouring agent Sunset Yellow (E110) which may cause allergic reactions.
12 4. 5 Interaktion med andre lægemidler og andre former for interaktion
11 4.5 Interaction with other medicinal products and other forms of interaction
Sikkerheden ved samtidig anvendelse af deferiprone og C- vitamin er ikke blevet formelt undersøgt. Baseret på de rapporterede utilsigtede interaktioner, der kan forekomme mellem deferoxamin og C- vitamin, bør der udvises forsigtighed ved samtidig indgivelse af deferiprone og C- vitamin.
Based on the reported adverse interaction that can occur between deferoxamine and vitamin C, caution should be used when administering deferiprone and vitamin C concurrently.
13 Nogle patienter fik progression af fibrosen, forbundet med en øgning af jernoverskuddet eller hepatitis C.
Some patients experienced progression of fibrosis associated with an increase in iron overload or hepatitis C.
Lave plasmazinkniveauer er blevet forbundet med deferiprone hos et mindre antal patienter.
12 Low plasma zinc levels have been associated with deferiprone, in a minority of patients.
Der er observeret neurologiske forstyrrelser (såsom cerebellare symptomer, diplopi, lateral nystagmus, nedsat psykomotorisk tempo, håndbevægelser og aksial hypotoni) hos børn, som igennem flere år frivilligt har fået ordineret mere end 2, 5 gang den maksimalt anbefalede dosis på 100 mg/ kg/ dagligt.
Neurological disorders (such as cerebellar symptoms, diplopia, lateral nystagmus, psychomotor slowdown, hand movements and axial hypotonia) have been observed in children who had been voluntarily prescribed more than 2.5 times the maximum recommended dose of 100 mg/ kg/ day for several years.
SYSTEMORGANKLASSE
COMMON COMMON
MEGET ALMINDELIG (≥1/ 10)
(≥ 1/ 10)
ALMINDELIG (≥1/ 100 TIL, < 1/ 10)
(≥ 1/ 100 to < 1/ 10) Increased liver enzymes Neutropenia Agranulocytosis Headache
IKKE ALMINDELIG (≥1/ 1. 000 TIL, < 1/ 100)
(≥ 1/ 1,000 to < 1/ 100)
Kliniske undersøgelser har vist, at deferiprone er effektivt til fremme af jernudskillelse, og at en dosis på 25 mg/ kg tre gange daglig kan forebygge progression af jernakkumulation vurderet ved
Clinical studies have demonstrated that deferiprone is effective in promoting iron excretion and that a dose of 25 mg/ kg three times per day can prevent the progression of iron accumulation as assessed by serum ferritin, in patients with transfusion-dependent thalassaemia.
Deferiprone er undersøgt hos 247 patienter i to fase III- undersøgelser og et såkaldt ‘ compassionate use ’ program.
13 Deferiprone has been investigated in 247 patients in two phase III trials and a compassionate use programme.
Middelkoncentrationerne af serum ferritin var ikke signifikant forskellige i de to behandlingsgrupper, men middelkoncentrationen af jern i leveren hos patienter behandlet med deferiprone synes at stige mere end hos patienter behandlet med deferoxamine.
The mean serum ferritin levels were not significantly different in the two treatment groups, but mean hepatic iron concentration in deferiprone treated patients seems to increase more than in deferoxamine treated patients.
Renset vand Hydroxyethylcellulose Glycerol Koncentreret saltsyre Kunstig kirsebærsmag Pebermynteolie Sunset Yellow (E110) Sucralose (E955)
Purified water Hydroxyethylcellulose Glycerol Hydrochloric acid, concentrated Artificial cherry flavour Peppermint oil Sunset Yellow (E110) Sucralose (E955)
2 år Skal anvendes inden 35 dage efter første åbning.
After first opening use within 35 days.
Gule- polyethylenterephthalat (PET) flasker med børnesikret lukke (polypropylen) og et gradueret målebæger (polypropylen).
Amber polyethylene terephthalate (PET) bottles with child resistant closure (polypropylene), and a graduated measuring cup (polypropylene).
25/ 08/ 1999
25/ 08/ 1999 Date of latest renewal:
17 BILAG II
17 A.
Bio Science Park Archimedesweg 2 2333 CN Leiden Holland
Bio Science Park Archimedesweg 2 2333 CN Leiden Netherlands
Lægemiddelovervågningssystem Indehaveren af markedsføringstilladelsen skal sikre, at det lægemiddelovervågningssystem, der er specificeret i version 01 (af 4. maj 2006) modul 1. 8. 1 af ansøgningen om markedsføringstilladelse, er på plads og fungerer, før og mens produktet markedsføres.
The MAH must ensure that the system of pharmacovigilance as described in version 01 (dated 4 May 2006) presented in Module 1.8.1 of the Marketing Authorisation Application is in place and functioning before and whilst the product is on the market.
Risikostyringsplan Indehaveren af markedsføringstilladelsen forpligter sig til at gennemføre de undersøgelser og supplerende lægemiddelovervågningsaktiviteter, der er specificeret i lægemiddelovervågningsplanen som anført i version 2 (af 19. september 2007) af risikostyringsplanen og i modul 1. 8. 2 af ansøgningen om markedsføringstilladelse og evt. efterfølgende opdateringer af risikostyringsplanen som aftalt med CHMP.
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan as agreed in version 2 (dated 19 September 2007) of the Risk Management Plan (RMP) presented in Module 1.8.2 of the Marketing Authorisation Application and any subsequent updates of the RMP agreed by the CHMP
I henhold til CHMP- vejledningen for risikostyringssystemer vedrørende lægemidler til human brug skal en opdateret plan for risikostyring indsendes samtidig med den næste periodiske sikkerhedsopdateringsrapport (PSUR).
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR).
Endvidere skal en opdateret RMP indsendes: • Når der modtages nye oplysninger, som kan påvirke den nugældende sikkerhedsspecifikation, lægemiddelovervågningsplan eller risikominimeringsaktiviteter. • Inden 60 dage, efter en vigtig milepæl (vedrørende lægemiddelovervågning eller risikominimering) er nået. • Efter anmodning fra EMEA.
In addition, an updated RMP should be submitted: • When new information is received that may impact on the current Safety specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 says of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA.
Indehaveren af markedføringstilladelsen skal fortsætte med at indsende PSURs hver 6. måned.
PSURs: the MAH will continue to provide Periodic Safety Update Reports every 6 months.
19 BILAG III
19 A.
ETIKETTERING
20 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Ferriprox 500 mg filmovertrukne tabletter deferiprone
Ferriprox 500 mg film-coated tablets deferiprone
En tablet indeholder 500 mg deferiprone
One tablet contains 500 mg deferiprone
Filmovertrukne tabletter 100 tabletter
Film-coated tablets 100 tablets
Må ikke opbevares over 30°C
Do not store above 30°C
22 11.
21 11.
23 OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE OG PÅ DEN INDRE EMBALLAGE
22 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Ferriprox 100 mg/ ml oral opløsning deferiprone
Ferriprox 100 mg/ ml oral solution Deferiprone
INDLÆGSSEDDEL
25 PACKAGE LEAFLET:
Ferriprox 500 mg filmovertrukne tabletter Deferiprone
Ferriprox 500 mg film-coated tablets Deferiprone
Læs denne indlægsseddel grundigt inden De begynder at tage medicinen. − Gem indlægssedlen.
Read all of this leaflet carefully before you start taking this medicine. − Keep this leaflet.
De kan få brug for at læse den igen. − Spørg lægen eller på apoteket, hvis der er mere, De vil vide. − Lægen har ordineret til Dem personligt.
You may need to read it again. − If you have any further questions, ask your doctor or pharmacist. − This medicine has been prescribed for you.
Det kan være skadeligt for andre, selvom de har de samme symptomer, som De har. − Hvis De bemærker nogen form for bivirkninger, som ikke er nævnt i denne indlægsseddel, bør De oplyse Deres læge eller apotek herom. − Sammen med denne folder finder du et reminderkort til patient/ plejer.
It may harm them, even if their symptoms are the same as yours. − If you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. − Attached to this leaflet you will find a patient/ carer reminder card.
Tag kortet af, udfyld det, læs det omhyggeligt, og sørg for at have det på dig.
You should detach, complete, read the card carefully and carry it with you.
Ferriprox virkning og hvad De skal bruge det til 2.
What Ferriprox is and what it is used for 2.
Det skal De vide, før De begynder at tage Ferriprox 3.
Before you take Ferriprox 3.
Sådan skal De tage Ferriprox 4.
How to take Ferriprox 4.
Sådan opbevarer De Ferriprox 6.
How to store Ferriprox 6.
FERRIPROX VIRKNING OG HVAD DE SKAL BRUGE DET TIL
WHAT FERRIPROX IS AND WHAT IT IS USED FOR
Ferriprox er et lægemiddel, som fjerner jern fra kroppen.
Ferriprox is a medicine that removes iron from the body.
Deferiprone er det aktive stof i Ferriprox.
Deferiprone is the active substance in Ferriprox.
Ferriprox er beregnet til behandling af jernoverbelastning hos patienter med thalassæmi major, som enten ikke må få behandling med deferoxamine eller hos hvem deferoxamine ikke virkede tilstrækkeligt.
Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE FERRIPROX
BEFORE YOU TAKE FERRIPROX
Tag ikke Ferriprox − Hvis De er overfølsom (allergisk) over for deferiprone eller et af de øvrige indholdsstoffer. − Hvis De tidligere har haft gentagne tilfælde af neutropeni (lavt neutrofiltal). − Hvis De tidligere har haft agranulocytose (meget lavt antal hvide blodlegemer < 0, 5 x 109/ l). − Hvis De for øjeblikket tager medicin, der vides at forårsage neutropeni. − Hvis De er gravid eller ammer.
Do not take Ferriprox − if you are allergic (hypersensitive) to deferiprone or any of the other ingredients of Ferriprox. − if you have a history of repeated episodes of neutropenia (low neutrophil count). − if you have a history of agranulocytosis (very low white blood cell count < 0.5x109/ l). − if you are currently taking medicines known to cause neutropenia. − if you are pregnant or breast-feeding.
Behandling med Ferriprox kan være forbundet med forekomst af et meget lavt antal hvide blodlegemer hos visse patienter.
Therapy with Ferriprox may be associated with the occurrence of a very low white blood cell count in some patients.
Denne tilstand kaldes alvorlig neutropeni eller agranulocytose og kan udsætte Dem for stor risiko for at udvikle alvorlig infektion.
This condition is known as severe neutropenia or agranulocytosis and may place you at risk of developing a serious infection.
Det vides ikke, på hvilken måde Ferriprox forårsager neutropeni.
The way Ferriprox causes neutropenia is not known.
Hvis De for øjeblikket tager medicin, der vides at forårsage neutropeni.
Patients must not take any medicines known to be associated with neutropenia or those that can cause agranulocytosis.
Vær ekstra forsigtig med at tage Ferriprox − Hvis De tidligere har haft neutropeni, da en af de mest alvorlige bivirkninger, der kan opstå, er et meget lavt antal hvide blodlegemer (neutrofil).
Take special care with Ferriprox − if you have a history of neutropenia, since one of the most serious side effects that may occur is a very low white blood cell (neutrophil) count.
Denne tilstand, der kaldes alvorlig neutropeni eller agranulocytose, er forekommet hos 1 ud af 100 mennesker, der har fået Ferriprox ved kliniske forsøg.
This condition, known as severe neutropenia or agranulocytosis, has occurred in about 1 out of 100 people who have taken Ferriprox in clinical studies.
Da hvide blodlegemer medvirker til at bekæmpe infektion, kan et meget lavt neutrofiltal udsætte Dem for stor risiko for at udvikle alvorlig og muligvis livstruende infektion.
Because white blood cells help to fight infection, a low neutrophil count may place you at risk of developing a serious and potentially life-threatening infection.
For at observere for neutropeni vil Deres læge jævnligt bede Dem om en blodprøve (for at kontrollere Deres hvide blodcelletal) helt op til en gang om ugen, mens De behandles med Ferriprox.
To monitor for neutropenia, your doctor will ask you to have a blood test (to check your white blood cell count) performed regularly, as frequently as every week, while you are being treated with Ferriprox.
Det er meget vigtigt, at De overholder alle disse konsultationer.
It is very important for you to keep all of these appointments.
Konferer venligst det reminderkort til
Please refer to the patient/ carer
27 patient/ plejer, der følger med denne folder.
26 reminder card attached to this leaflet.
Fortæl omgående Deres læge om eventuelle symptomer, der tyder på infektion, så som feber, ondt i halsen eller influenzalignende symptomer.
Report immediately to your doctor any symptoms of infection such as fever, sore throat or flu-like symptoms.
Deres læge vil også bede Dem møde til undersøgelser for at kontrollere Deres krops jernbelastning.
Your doctor will also ask you to come in for tests to monitor body iron load.
Derudover vil han eller hun måske bede Dem få taget nogle leverbiopsier.
In addition he or she also might ask you to undergo liver biopsies.
Brug af anden medicin Hvis De tager eller for nylig har taget andre lægemidler, skal De oplyse Deres læge eller apotek herom, også hvis der er tale om ikke- receptpligtige lægemidler.
Taking other medicines Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.
Spørg lægen eller på apoteket, før De tager vitamin C sammen med Ferriprox.
Please consult with your doctor or pharmacist before taking vitamin C with Ferriprox.